CDKAL1 and HHEX are associated with type 2 diabetes-related traits among Yup'ik people. by Klimentidis, Yann C et al.
UC Davis
UC Davis Previously Published Works
Title
CDKAL1 and HHEX are associated with type 2 diabetes-related traits among Yup'ik people.
Permalink
https://escholarship.org/uc/item/6wx45211
Journal
Journal of diabetes, 6(3)
ISSN
1753-0393
Authors
Klimentidis, Yann C
Lemas, Dominick J
Wiener, Howard H
et al.
Publication Date
2014-05-01
DOI
10.1111/1753-0407.12093
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
CDKAL1 and HHEX are associated with type-2 diabetes-related
traits among Yup’ik people
Yann C. KLIMENTIDIS1, Dominick J. LEMAS2, Howard H. WIENER3, Diane M. O’BRIEN4,
Peter J. HAVEL5,6, Kimber L. STANHOPE5,6, Scarlett E. HOPKINS4, Hemant K. TIWARI7,
and Bert B. BOYER4,*
1Mel and Enid Zuckerman College of Public Health, Division of Epidemiology and Biostatistics,
University of Arizona, Tucson, AZ, 85724
2Department of Pediatrics, Section of Neonatology, University of Colorado Denver, Aurora, CO
80045
3Department of Epidemiology, University of Alabama at Birmingham, Birmingham, AL 35294
4Center for Alaska Native Health Research, Institute of Arctic Biology, University of Alaska
Fairbanks, Fairbanks, AK 99775
5Department of Molecular Biosciences, School of Veterinary Medicine, University of California,
Davis, Davis, CA 95616
6Department of Nutrition, University of California, Davis, Davis, CA 95616
7Section on Statistical Genetics, Department of Biostatistics, University of Alabama at
Birmingham, Birmingham, AL 35294
Abstract
Background: Genome-wide association studies (GWAS) have identified single nucleotide
polymorphisms (SNPs) associated with type-2 diabetes (T2D), mainly among individuals of
European ancestry. We examined the frequency of these SNPs and their association with T2D-
related traits in an Alaska Native study population with a historically low prevalence of T2D. We
also investigated whether dietary characteristics that may protect against T2D, such as n-3
polyunsaturated fatty acid (n-3 PUFA) intake, modify these associations.
Methods: In 1,144 Yup’ik people, we examined 17 SNPs repeatedly identified in GWAS for
individual and cumulative associations with T2D-related traits. Cumulative associations were
evaluated using a genetic risk score (GRS) calculated by summing risk alleles. Associations were
tested for interactions with sex, BMI, and n-3 PUFA intake.
Results: The rs7754840 SNP in CDKAL1 is significantly associated with HbA1c (p=0.00091).
The rs5015480 SNP near HHEX is significantly associated (in opposite direction to that in
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Significant findings of the study: We examine and compare the frequency of T2D-associated SNPs in Yup’ik people. SNPs in
CDKAL1 and HHEX are found to be associated with glycemic traits in this sample. Associations are not modified by BMI or dietary
n-3 PUFA intake.
What this study adds: This is the first study to examine the frequency of T2D SNPs in an Alaska Native population, which has a
historically low prevalence of T2D. We examine associations between SNPs and glycemic traits, and interactions with BMI and n-3
PUFA intake.
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Europeans) with a combined fasting glucose (FG) and HbA1c measure (p=0.00046) and with
HOMA-B (p=0.0014). The GRS is significantly associated with FG and combined FG & HbA1c
only when the HHEX SNP is dropped from the GRS. Associations are not modified by BMI or n-3
PUFA intake.
Conclusion: Our results highlight the potential importance of CDKAL1 and HHEX in glucose
homeostasis in this Alaska Native population with a low prevalence of T2D, and suggest that these
loci should be examined in greater detail in this population.
Keywords
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INTRODUCTION
Type-2 diabetes (T2D) is a major health concern, often disproportionately affecting Nativfe
American populations.1–3 Prior to the 1980s, epidemiological studies demonstrated that T2D
among Alaska Native people was a rare condition.4 Despite data suggesting that the
prevalence of T2D is increasing among coastal Alaska Native communities, Yup’ik people
from Southwest Alaska continue to demonstrate a T2D prevalence (4 to 6%) that is lower
compared to the overall US population (8%), and may be independent of obesity
status.1,2,5,6The mechanisms that allow Yup’ik people to carry excess body fat without
developing T2D at the same rate as other populations may involve dietary and genetic
factors.
Several studies suggest that genetic factors partially underlie T2D and related traits.7,8
Genome-wide association studies (GWAS) for T2D and related traits have been performed
mainly among individuals of European descent.9–11 Subsequent studies have found evidence
of consistent associations of these SNPs across populations12–14, although associations at
some loci, such as TCF7L2, do not appear to be generalizable.15Currently, little is known
regarding the frequency of these SNPs among Alaska Native people, and whether they are
associated with T2D traits.
Epidemiologic studies have reported a lower prevalence of impaired glucose tolerance and
T2D in populations consuming large amounts of n-3 PUFAs found mainly in fish and
marine mammals.16 Yup’ik people have an unusually high variability in n-3 PUFA intake,
because fish and marine mammals are an important part of the traditional diet, but adherence
to this diet is highly variable.17,18 Consumption of n- PUFAs may contribute to the low
prevalence of T2D in this group,19 and genetic factors may mediate this association.
Understanding the genetic mechanisms and dietary interactions underlying T2D
pathophysiology will require knowledge regarding how loci identified in T2D GWAS are
associated with specific T2D-related quantitative traits. Previous studies suggest
considerable overlap of loci associated with T2D and related quantitative traits,10,20,21 and
that distinct genetic factors underlie each of these quantitative traits.22,23
In this study, we determine the extent to which 17 T2D-associated SNPs identified in the
first wave of GWAS and confirmed in recent GWAS meta-analyses, are polymorphic, are
associated with glycemic traits , and interact with n-3 PUFA intakein a sample of 1,144
Yup’ik people from a population with a historically low prevalence of T2D..
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METHODS
Study sample
Through the Center for Alaska Native Health Research (CANHR), Yup’ik participants were
recruited in 11 southwest Alaska communities to participate in a study examining genetic,
behavioral, and dietary factors underlying metabolic traits. . The sample used here consists
of 1,144 non-pregnant self-identified Yup’ik people between the ages of 14 and 94.
Summary statistics regarding family structure among participants were calculated using
PEDINFO in the Statistical Analysis for Genetic Epidemiology (S.A.G.E., 2009) software.
The sample consists of 49 founders, 969 non-founders, and 123 singletons. There were 195
pedigrees with a mean size of 11.44 individuals (range, 1-894) and 696 sibships with a mean
size of 1.39 individuals (range, 1-9). The age distribution in this study resembles the age
distribution among eligible participants, according to the 2000 US Census data. Informed
consent was obtained from all participants using protocols approved by the University of
Alaska Institutional Review Board, the National and Alaska Area Indian Health Service
Institutional Review Boards, and the Yukon Kuskokwim Health Corporation Human Studies
Committee.
Phenotypic and dietary measurements
Height and weight measurements were obtained by trained staff using protocols from the
NHANES (National Health and Nutrition Examination Survey) III Anthropometric
Procedures Manual,24 as previously described.5 Fasting insulin (FI) was assayed with
radioimmunoassay kit using an I125 –iodinated insulin tracer, anti-human insulin specific
antibody, and human insulin standards from Linco Research where the intra- and inter-
assay variations were 5.8% and 10.2%, respectively. Fasting blood glucose (FG) was
measured on a Cholestech LDX analyzer, and glycosylated hemoglobin (HbA1c) was
measured on a Bayer HbA1C DCA 2000+ analyzer (Bayer AG, Leverkusen, Germany). We
calculated HOMA-IR (homeostatic model assessment of insulin resistance) as the product of
FG and FI divided by 22.5, and HOMA-B (homeostatic model assessment of beta-cell
function) as (FI * 360) / (FG – 63).25 Finally, we defined a continuous variable called ‘FG &
HbA1c’ based on previous studies indicating that combined information from FG and HbA1c
is a reliable predictor of developing T2D.26,27 The FG & HbA1c variable was calculated by
first standardizing each variable to have a standard deviation of 1, then using the mean of the
two standardized variables. Data on diabetes-related medications (metformin, glyburide,
pioglitazone) were obtained through self-report at the time participants were enrolled in the
study, and extracted from the Yukon Kuskokwim Health Corporation medical records by a
trained nurse. Long-chain n-3 PUFA intake was assessed using the nitrogen stable isotope
ratio (15N/14N) of red blood cells, as previously described.18,28
Genotypes
Genes selected for this study included those identified in the first wave of GWAS for
T2D,29–32 and also replicated in a meta-analysis.10 Specific SNPs within or near each gene
were selected based on which has been associated with T2D in more than one GWAS, as of
June, 2011. Genotyping was conducted at the Broad Institute (Cambridge, MA) using a
Sequenom iPLEX platform.33 The FTO SNP (rs9939609) was previously investigated for
association with body composition traits in this sample.34 We excluded SNPs with> 10%
missing frequency or a minor allele frequency < 1%. Allele frequencies and deviations from
Hardy-Weinberg equilibrium were evaluated using MENDEL software,35 accounting for
family structure. We compared allele frequencies in this sample to those in five HapMap
reference populations.36
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Genetic risk score
A genetic risk score (GRS) was calculated for all individuals with at least six non-missing
genotypes for the fourteen SNPs considered. Risk alleles were defined as those which are
positively associated with T2D risk in GWAS. The sum of risk alleles was divided by the
number of non-missing genotypes, to account for missing genotypes. We also used a
weighted GRS, with weights corresponding to published T2D odds ratios.10
Statistical analyses
Linear models were fit to each phenotype using the following covariates: age, sex, BMI,
medication use, and community location. We ran analyses with and without BMI as a
covariate to evaluate the extent to which significant associations with T2D-related traits
were mediated by obesity. The community location variable is based on the second principal
component from a principal components analysis (PCA) of 4,108 autosomal markers, as
previously described,28 and corresponds to the proximity of each community to the coast. It
is included as a covariate in the analyses to control for population stratification. The first
component from this PCA had no obvious systematic structure, as previously described.37
As a sensitivity analysis, we examined the effect of controlling for the first PC on our main
findings.. The distributions of residuals from linear models were examined for normality,
and Box-Cox transformations 38 and extreme outlier removal were implemented for each
phenotype that deviated from the normality assumption.
We accounted for within-pedigree correlation using the linear mixed effects model (LME)
implemented in the ‘lmekin’ function in the coxme package (http://cran.r-project.org/web/
packages/coxme/index.html) 39 to test the association between each phenotype and each
SNP, using an additive genetic model. We tested the cumulative association of these SNPs
with each phenotype using the GRS, including the same covariates listed above . We also
examined interactions with sex, BMI, and n-3 PUFA intake. We used a Bonferroni
correction for multiple testing (14 tests) in the single SNP analyses (α=3.57 × 10−3).
RESULTS
Descriptive Statistics
The sample consists of 540 males and 604 females. Mean phenotypic values for the entire
sample and for each sex are listed in Table 1. Females have significantly higher BMI, FG,
FI, HOMA-IR, and HOMA-B, and significantly lower FG. Thirteen individuals reported
taking T2D-related medication. After excluding outliers (FG>215, HbA1c>9) and
individuals taking medication, we find that 0.97% of individuals have a FG above 125 mg/
dL, 1.3% of individuals have an HbA1c equal or greater than 6.5%, 20% have a FG between
100 and 125 mg/dL, and 24% of individuals have an HbA1c between 5.7 and 6.4%.
Two of the 17 SNPs (rs10923931-NOTCH2 and rs7578597-THADA) had an extremely low
MAF (<0.01), and one SNP had a missing rate > 10% (rs1801282 – PPARg), thus
precluding them from analyses.. Our analysis therefore included a total of 14 SNPs. The
frequency of the risk allele for each SNP in this sample and in selected HapMap populations
is listed in Table 2. The allele frequencies in Yup’ik people do not differ appreciably from
that of geographically close populations (e.g. CHB). All SNPs are in Hardy Weinberg
equilibrium after correction for multiple testing (p > 0.0036).
Association of individual SNPs and n-3 PUFA with phenotypes
We find that n-3 PUFA intake is positively and significantly associated with HbA1c
(p=0.02), after adjusting for covariates.
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We find that 10 of the 14 SNPs are associated with increased HbA1c and FI in a direction
consistent with GWAS findings for T2D. 9 out of 14 SNPs are associated with FG, FI,
HOMA-IR, and the combined FG & HbA1c measure in a direction consistent with T2D
GWAS. 8 out of 14 T2D GWAS risk alleles are associated with a decrease in HOMA-B (see
Table 3).
The only statistically significant SNP associations, after correction for multiple testing, are
between rs7754840 (CDKAL1) and HbA1c (p=9.1 × 10−4), and between rs5015480 (HHEX)
and the combined FG & HbA1c measure (p=4.6 × 10−4), as well as with HOMA-B (p=1.4 ×
10−3) (see Table 3). These associations do not appear to be driven principally by BMI, as the
strength of association differs minimally upon adjusting for BMI (see Table 3). Controlling
for the 1st PC very slightly attenuated the strength of both associations, but results were still
statistically significant. Interestingly, the associations with the SNP in HHEX are in the
opposite direction compared to GWAS findings. The present analysis revealed that the T
allele is associated with higher trait values (and lower HOMA-B), while in GWAS, the C
allele is associated with greater T2D risk. Variation at rs7754840 explains approximately
0.8% of variation in HbA1c, and variation at rs5015480 explains approximately 0.8% of
variation in FG & HbA1c and HOMA-B. The association between the MTNR1B SNP
(rs10830963) and HOMA-B is marginally significant (p=6.4 × 10−3).
We found no evidence that associations were significantly modified by BMI, sex, or n-3
PUFA intake (see Supplementary Table 1-3). Based on a previous study that found that the
associations between both CDKAL1 and HHEX variants and T2D risk were stronger in
females than males 40, we examined associations stratified by sex. The association between
rs7754840 (CDKAL1) and HbA1c is significant in females (p=0.00053), but not in males
(p=0.35). The p-value for the interaction of this SNP and sex is nominally significant
(p=0.013).
Association of T2D GRS with phenotypes
The T2D GRS is positively associated with all phenotypes, although none of the
associations are statistically significant (see Table 3). Since the associations with the HHEX
SNP were in the opposite direction in this sample, compared to GWAS, we computed a GRS
excluding this SNP. We find that this GRS is positively and significantly associated with FG
& HbA1c (p=0.014) and with FG (p=0.021). The proportion of variance in these traits
explained by this modified GRS is 1.2% or less. Results did not improve or change
significantly with a weighted GRS. Using a risk score without CDKAL1 (and without
HHEX), the p-value for association increases to 0.11 for FG & HbA1c and to 0.055 for FG.
We examined risk scores in which only nominally significant (p<0.05) SNPs in a consistent
direction are included in the score. For FG, a risk score comprised of IGF2BP2 and
MTNR1B is nearly significantly associated with fasting glucose (p=0.05). For the other
traits, there are either no nominally significant associations with any SNPs, or the only
significant SNP (in a consistent direction) is CDKAL1 or MTNR1B.
Using the GRS without the HHEX SNP, we find no evidencethat associations between the
GRS and FG and FG & HbA1c are modified by sex, BMI, or n-3 PUFA intake.
DISCUSSION
We examined whether SNPs identified in T2D GWAS among individuals of European
descent are associated with T2D-related traits among Yup’ik people who have a historically
low prevalence of T2D. The prevalence of prediabetes (defined as HbA1c greater than 5.6
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but less than or equal to 6.5, or FG greater than 99 but less than 126) in this sample of
Yup’ik people was relatively low (22%), compared to 35% in the adult US population.41
Variation in CDKAL1 (rs7754840) was significantly associated with HbA1c. This SNP is
located within intron 5 of the CDKAL1 (CDK5 regulatory subunit associated protein 1-like
1) gene.CDKAL1 variants have been found to be associated with reduced beta-cell glucose
sensitivity and reduced insulin secretion.42,43 A GWAS for HbA1c among normoglycemic
Koreans identified CDKAL1 as most strongly associated with HbA1c,44 and a study among
healthy Japanese men found an association between CDKAL1 and HbA1c.45 As previously
reported in a cohort of Korean individuals,40 we find that this association is stronger among
females than males.
Variation near HHEX (rs5015480) was significantly associated with FG & HbA1c and
HOMA-B. This SNPis located upstream of the HHEX (hematopoietically expressed
homeobox) gene which has been found to be involved in ventral pancreatic development by
controlling the proliferation rate of endodermal cells.46 This SNP was previously found to
be associated with decreasedinsulin response and beta-cell glucose sensitivity.47 Both
CDKAL1 and HHEX variants were strongly associated with T2D and insulin secretion in
several Southeast Asian cohorts and among Pima Indians, respectively.54,55 Our finding that
the risk allele for the HHEX SNP as identified in GWAS corresponds to the “protective”
allele in this sample is not uncommon in genetic studies,48 and may be attributed to
population-unique linkage-disequilibrium patterns, or that the identified SNP is likely not
the causal variant. The marginally significant association between rs10830963 in MTNR1B
(melatonin receptor 1B) and HOMA-B is consistent with previous findings showing that
variation in MTNR1B is associated with HOMA-B and other insulin secretion
measures.49–51MTNR1B is expressed in pancreatic islets, and has been implicated in the
regulation of circadian rhythms and insulin secretion.52,53
Finally, our analysis revealed the GRS without the HHEX SNP was significantly associated
with FG and FG & HbA1c, although these associations appear to be driven in large part by
the associations with CDKAL1.
The strengths of this study include detailed phenotypic measurements in a population with a
historically low prevalence of T2D and highly variable PUFA intake. However, there are
limitations that should be noted. Measures of HbA1c can partly reflect other hematological
traits such as hemoglobinopathies,56 therefore potentially confounding associations.
Secondly, we have no estimate of total caloric or fat intake in the entire sample to include as
a covariate in associations involving n-3 PUFA intake, making it difficult to interpret our
finding of a positive association between n-3 PUFA intake and HbA1c. For a subset of
participants (n=515), total energy and percentage fat intake (% of total calories) data from
24 Hour Recall was available. Within this subset, the association between n-3 PUFA intake
and HbA1c is unchanged upon including total energy intake as a covariate. However, upon
including % fat intake as a covariate, the association is no longer statistically significant
(data not shown), suggesting that additional work is needed to understand the relationship
between n-3 PUFA intake and T2D traits.
It should be noted that the discovery of additional T2D susceptibility variants has continued
in recent years, with the total number of confirmed SNPs up to approximately 65.20 SNPs
included in our study were identified in the first wave of GWAS meta-analysis and may be
those with relatively larger effect sizes. Nevertheless, we acknowledge that there are likely
hundreds or thousands of variants implicated inT2D.Our results show that Yup’ik study
participants have a low prevalence of prediabetes relative to other populations, and that
CDKAL1 and HHEX variants are associated with FG and HbA1c. Future studies should fully
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characterize variation in the regions surrounding these genes in an effort to elucidate how
the molecular mechanisms underlying these phenotypes are mediated by genetic variation
and interact with lifestyle and behavioral factors.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1
Descriptive Statistics (s.d.: standard deviation, * denotes statistically significant difference between males and
females)
Mean (s.d.) Males (n=540) Females (n=604)
Age 36.85 (17.35) 35.97 (17.34) 37.63 (17.33)
BMI (kg/m2) * 27.40 (6.08) 25.93 (4.82) 28.7 (6.76)
Fasting glucose (mg/dL) * 93.14 (10.98) 94.30 (11.20) 92.10 (10.69)
HbA1c (%) 5.46 (0.39) 5.49 (0.35) 5.43 (0.42)
Fasting insulin (mU/L) * 14.62 (8.08) 13.49 (7.33) 15.58 (8.55)
HOMA-IR * 3.43 (2.27) 3.21 (2.21) 3.62 (2.30)
HOMA-B * 189.8(117.7) 167.1 (96.7) 209.0 (130.0)
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Table 2
T2D risk SNPs, nearest gene, and allele frequencies.
Risk allele frequency in reference populations
SNP Gene Risk allele Risk allele frequency in sample YRI CEU CHB JPT MXL
rs4607103 ADAMTS9 C 0.60 0.69 0.79 0.57 0.60 0.67
rs4402960 IGF2BP2 T 0.28 0.53 0.31 0.27 0.33 0.21
rs7754840 CDKAL1 C 0.44 0.68 0.32 0.43 0.41 0.30
rs864745 JAZF1 T 0.60 0.78 0.49 0.77 0.82 0.64
rs13266634 SLC30A8 C 0.61 0.93 0.76 0.55 0.55 0.78
rs10811661 CDKN2A T 0.79 0.97 0.82 0.58 0.54 0.87
rs12779790 CDC123 G 0.11 0.11 0.25 0.19 0.11 0.12
rs5015480 HHEX C 0.35 0.62 0.57 0.20 0.19 0.51
rs7901695 TCF7L2 C 0.08 0.40 0.34 0.03 0.03 0.24
rs2237892 KCNQ1 C 0.59 0.90 0.92 0.65 0.62 0.76
rs5215 KCNJ11 C 0.40 0.02 0.37 0.38 0.35 0.42
rs7961581 TSPAN8 C 0.08 0.18 0.26 0.18 0.24 0.14
rs10830963 MTNR1B G 0.32 0.03 0.26 0.45 0.46 0.22
rs9939609 FTO A 0.16 0.50 0.46 0.15 0.19 0.23
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Table 3: Association of T2D SNPs with T2D-related quantitative traits with and without adjustment for BMI.
Reference allele refers to the risk allele as determined by GWAS in Europeans.
SNP Gene
Ref.
&
risk
Allele
FG FI HbA1c FG & HbA1c HOMA-IR HOMA-B
rs4607103 ADAMTS9 C −0.091,p=0.57 0.21, p=0.25 0.06, p=0.75 6 × 10−5, p=1 0.01, p=0.38 0.03, p=0.16
w/out BMI −0.096, p=0.56 0.28, p=0.17 0.03, p=0.88 −0.0003, p=0.99 0.02, p=0.27 0.03, p=0.11
rs4402960 IGF2BP2 T 0.429, p=0.021 0.1, p=0.65 −0.09, p=0.68 0.04, p=0.22 0.03, p=0.13 −0.03, p=0.25
w/out BMI 0.36, p=0.059 −0.07, p=0.78 −0.19, p=0.42 0.03, p=0.49 0.01, p=0.51 −0.04, p=0.12
rs7754840 CDKAL1 C 0.222, p=0.18 0.13, p=0.48 0.68, p=0.00091 0.08, p=0.012 0.01, p=0.37 −0.01, p=0.59
w/out BMI 0.203, p=0.23 0.14, p=0.52 0.72, p=0.00074 0.08, p=0.012 0.02, p=0.4 −0.01, p=0.62
rs864745 JAZF1 T 0.179, p=0.28 0.06, p=0.74 0.08, p=0.7 0.03, p=0.41 0.01, p=0.59 −0.01, p=0.49
w/out BMI 0.204, p=0.23 0.05, p=0.82 0.05, p=0.8 0.02, p=0.46 0.01, p=0.67 −0.02, p=0.45
rs13266634 SLC30A8 C 0.123, p=0.45 0.16, p=0.4 0.05, p=0.81 0.02, p=0.51 0.01, p=0.66 0.02, p=0.34
w/out BMI 0.133, p=0.43 0.23, p=0.27 0.09, p=0.65 0.03, p=0.39 0.01, p=0.47 0.02, p=0.28
rs10811661 CDKN2A T −0.067, p=0.73 −0.25, p=0.27 0.04, p=0.89 0.01, p=0.77 −0.01, p=0.63 −0.03, p=0.32
w/out BMI −0.07, p=0.73 −0.21, p=0.41 0.04, p=0.88 0.02, p=0.7 −0.01, p=0.8 −0.02, p=0.37
rs12779790 CDC123 G 0.374, p=0.17 0.21, p=0.49 0.05, p=0.87 0.07, p=0.21 0.03, p=0.32 −0.005, p=0.9
w/out BMI 0.341, p=0.22 0.07, p=0.84 0.07, p=0.85 0.07, p=0.23 0.02, p=0.58 −0.01, p=0.7
rs5015480 HHEX C −0.496, p=0.0043 0.21, p=0.29 −0.61, p=0.0046 −0.12, p=0.00046 −0.01, p=0.49 0.07, p=0.0014
w/out BMI −0.395, p=0.027 0.35, p=0.11 −0.49, p=0.03 −0.1, p=0.0066 0.002, p=0.91 0.08, p=0.00064
rs7901695 TCF7L2 C −0.263, p=0.42 0.28, p=0.47 −0.69, p=0.094 −0.1, p=0.11 0.004, p=0.9 0.04, p=0.34
w/out BMI −0.325, p=0.33 0.21, p=0.62 −0.71, p=0.097 −0.11, p=0.1 −0.001, p=0.98 0.04, p=0.41
rs2237897 KCNQ1 C 0.222, p=0.19 0.16, p=0.45 −0.15, p=0.5 0.03, p=0.39 0.02, p=0.23 −0.02, p=0.41
w/out BMI 0.344, p=0.066 0.05, p=0.81 −0.2, p=0.4 0.02, p=0.63 0.01, p=0.51 −0.02, p=0.32
rs5215 KCNJ11 C 0.0425, p=0.8 −0.25, p=0.21 0.15, p=0.49 0.01, p=0.69 −0.01, p=0.5 −0.02, p=0.28
w/out BMI −0.043, p=0.8 −0.41, p=0.056 0.02, p=0.92 −0.01, p=0.85 −0.03, p=0.17 −0.03, p=0.13
rs10830963 MTNR1B G 0.4234, p=0.018 −0.3, p=0.15 0.27, p=0.23 0.06, p=0.073 0.004, p=0.84 −0.06, p=0.0064
w/out BMI 0.431, p=0.018 −0.41, p=0.073 0.15, p=0.51 0.05, p=0.19 −0.005, p=0.8 −0.07, p=0.0029
rs7961581 TSPAN8 C −0.00083, p=1 −0.23, p=0.5 0.05, p=0.9 −0.01, p=0.82 −0.01, p=0.63 −0.02, p=0.65
w/out BMI 0.077, p=0.81 −0.14, p=0.71 −0.03, p=0.94 −0.01, p=0.82 −0.01, p=0.84 −0.01, p=0.81
rs9939609 FTO A −0.272, p=0.22 8 × 10−5, p=1 −0.04, p=0.88 −0.03, p=0.48 −0.01, p=0.7 0.03, p=0.33
w/out BMI −0.145, p=0.52 0.35, p=0.21 0.06, p=0.84 −0.002, p=0.96 0.02, p=0.4 0.05, p=0.086
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Table 4
Association of T2D genetic risk score (GRS) with T2D-related quantitative traits. (p-values shown;
statistically significant associations shown in bold)
FG FI HbA1c FG & HbA1c HOMA-IR HOMA-B
GRS 0.17 0.50 0.42 0.21 0.238 0.7
GRS without
HHEX
0.021 0.75 0.08 0.014 0.148 0.15
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